James C. Kennedy

TL;DR: In the ongoing clinical trial of ALA-induced Pp IX photodynamic therapy, the response rate for basal cell carcinomas following a single treatment has been 90% complete response and 7.5% partial response for the first 80 lesions treated.

TL;DR: Preclinical studies in experimental animals and human volunteers indicate that ALA can induce a localized tissue-specific photosensitization if administered by intradermal injection, opening the possibility of using ALA-induced PpIX to treat tumors that are too thick or that lie too deep to be accessible to either topical or locally injected ALA.

TL;DR: The current state of knowledge of the mechanisms of endogenous topical and systemic photosensitization using ALA, the results of published clinical trials, and possible methods of increasing the efficacy of endogenous photosensItization for ALA PDT are reviewed in this paper.

TL;DR: Using this system, it is found possible to obtain good emission and excitation spectra of the material responsible for the weak red fluorescence that characterizes normal mouse skin, and to follow the biosynthesis and subsequent clearance of protoporphyrin IX in the skin of non‐anesthetized mice that had been given various doses of the porphyrIn precursor 5‐aminolevulinic acid.

TL;DR: A two-fold mechanism of selective biodistribution is advanced, one involving normal tissue vs. tumor tissue selectivity, the other involving intracellular vs. intercellular distribution of sensitizer ionic species.